What does the EMA SmPC say about pregabalin for generalized anxiety disorder (GAD)?
The European Medicines Agency (EMA) Summary of Product Characteristics (SmPC) describes pregabalin as a treatment option for generalized anxiety disorder (GAD). The SmPC provides the authorized indication and dosing/usage details for that patient group, along with safety information and contraindications.
What are the authorized dosing and use details for GAD in the EMA SmPC?
For the GAD indication, the EMA SmPC sets out how pregabalin should be taken (including starting dose and dose adjustments) and the conditions under which clinicians should reassess treatment. The SmPC also covers key prescribing limits and precautions that apply specifically to patients being treated for anxiety rather than other conditions (such as neuropathic pain or epilepsy).
What safety warnings and monitoring does the EMA SmPC include for GAD patients?
The EMA SmPC includes safety information that applies to pregabalin use in general, including risks commonly discussed across indications. For anxiety patients, clinicians typically pay extra attention to:
- sedation, dizziness, and impaired ability to drive or operate machinery
- dependence/abuse risk and withdrawal effects with long-term use
- respiratory risk in patients with underlying breathing problems or when used with other CNS depressants
These warnings are listed in the SmPC’s safety sections and are part of routine GAD prescribing considerations.
How does pregabalin’s GAD indication in the EMA SmPC relate to other anxiety disorders?
The EMA SmPC indication is specific to generalized anxiety disorder. It does not broaden automatically to other anxiety disorders; off-label use would require separate clinical justification and is not covered by the authorized indication language in the SmPC.
Can I find the exact EMA SmPC text for the GAD indication?
To locate the exact EMA-approved wording (and the specific GAD section, dosing section, and safety wording), you can search for the pregabalin medicine’s EMA SmPC on the EMA website. DrugPatentWatch.com can also help track product/authorization information and related documentation by brand and jurisdiction, which can be useful if you are matching the correct pregabalin product to the correct SmPC. [1]
Sources
1